MX2023001936A - Método de elaboración de aav recombinantes. - Google Patents
Método de elaboración de aav recombinantes.Info
- Publication number
- MX2023001936A MX2023001936A MX2023001936A MX2023001936A MX2023001936A MX 2023001936 A MX2023001936 A MX 2023001936A MX 2023001936 A MX2023001936 A MX 2023001936A MX 2023001936 A MX2023001936 A MX 2023001936A MX 2023001936 A MX2023001936 A MX 2023001936A
- Authority
- MX
- Mexico
- Prior art keywords
- aav
- particles
- recombinant
- host cells
- recombinant aav
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000002245 particle Substances 0.000 abstract 4
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000010415 tropism Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
- C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2013057.1A GB202013057D0 (en) | 2020-08-21 | 2020-08-21 | Method of making recombinant aavs |
| PCT/GB2021/052162 WO2022038369A1 (en) | 2020-08-21 | 2021-08-20 | Method of making recombinant aavs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001936A true MX2023001936A (es) | 2023-04-10 |
Family
ID=72660685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001936A MX2023001936A (es) | 2020-08-21 | 2021-08-20 | Método de elaboración de aav recombinantes. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240026378A1 (enExample) |
| EP (1) | EP4200428B1 (enExample) |
| JP (2) | JP7853958B2 (enExample) |
| KR (1) | KR20230074485A (enExample) |
| CN (1) | CN116419974A (enExample) |
| AU (1) | AU2021327855A1 (enExample) |
| CA (1) | CA3189844A1 (enExample) |
| GB (1) | GB202013057D0 (enExample) |
| MX (1) | MX2023001936A (enExample) |
| WO (1) | WO2022038369A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110892064A (zh) | 2017-07-25 | 2020-03-17 | 牛津遗传学有限公司 | 腺病毒载体 |
| GB201901571D0 (en) | 2019-02-05 | 2019-03-27 | Oxford Genetics Ltd | Inducible AAV sysyem |
| US12054738B2 (en) | 2020-07-30 | 2024-08-06 | Shape Therapeutics Inc. | Stable cell lines for inducible production of rAAV virions |
| JP2024537896A (ja) | 2021-10-18 | 2024-10-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 |
| AR127674A1 (es) | 2021-10-18 | 2024-02-21 | Regeneron Pharma | Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2453405A1 (en) | 2001-07-13 | 2003-01-23 | University Of Iowa Research Foundation | Pseudotyped adeno-associated viruses and uses thereof |
| AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
| US7220577B2 (en) | 2002-08-28 | 2007-05-22 | University Of Florida Research Foundation, Inc. | Modified AAV |
| US8632764B2 (en) * | 2008-04-30 | 2014-01-21 | University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| CN110892064A (zh) | 2017-07-25 | 2020-03-17 | 牛津遗传学有限公司 | 腺病毒载体 |
| FR3069668B1 (fr) | 2017-07-27 | 2021-02-12 | Safran | Procede et dispositif de recherche d'un defaut susceptible d'affecter un dispositif mecanique tournant de transmission de puissance |
-
2020
- 2020-08-21 GB GBGB2013057.1A patent/GB202013057D0/en not_active Ceased
-
2021
- 2021-08-20 MX MX2023001936A patent/MX2023001936A/es unknown
- 2021-08-20 WO PCT/GB2021/052162 patent/WO2022038369A1/en not_active Ceased
- 2021-08-20 CA CA3189844A patent/CA3189844A1/en active Pending
- 2021-08-20 AU AU2021327855A patent/AU2021327855A1/en active Pending
- 2021-08-20 CN CN202180067893.XA patent/CN116419974A/zh active Pending
- 2021-08-20 JP JP2023512464A patent/JP7853958B2/ja active Active
- 2021-08-20 US US18/021,675 patent/US20240026378A1/en active Pending
- 2021-08-20 KR KR1020237009622A patent/KR20230074485A/ko active Pending
- 2021-08-20 EP EP21759123.9A patent/EP4200428B1/en active Active
-
2026
- 2026-04-17 JP JP2026068682A patent/JP2026123082A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026123082A (ja) | 2026-07-29 |
| CA3189844A1 (en) | 2022-02-24 |
| WO2022038369A1 (en) | 2022-02-24 |
| US20240026378A1 (en) | 2024-01-25 |
| AU2021327855A9 (en) | 2023-07-13 |
| KR20230074485A (ko) | 2023-05-30 |
| GB202013057D0 (en) | 2020-10-07 |
| EP4200428B1 (en) | 2025-02-19 |
| CN116419974A (zh) | 2023-07-11 |
| JP7853958B2 (ja) | 2026-04-30 |
| AU2021327855A1 (en) | 2023-05-04 |
| EP4200428A1 (en) | 2023-06-28 |
| JP2023538409A (ja) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001360A1 (es) | Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis. | |
| PE20190129A1 (es) | Capsides variantes de virus adenoasociados y metodos de uso de estas | |
| MX2020001593A (es) | Moleculas de acido nucleico y usos de las mismas. | |
| MX2020006764A (es) | Una proteína de la cápside de raav modificada para terapia génica. | |
| CL2021002881A1 (es) | Composiciones útiles en el tratamiento de leucodistrofia metacromática | |
| BR112021018776A2 (pt) | Vetores de vírus adenoassociado recombinante | |
| CO2018012513A2 (es) | Anticuerpos | |
| BR112019001887A2 (pt) | composições e métodos para o tratamento de doença associada a cep290 | |
| JP2020508648A5 (enExample) | ||
| MX2017012097A (es) | Variantes de virus adenoasociado y métodos de uso de estas. | |
| BR112022000724A2 (pt) | Proteínas de capsídeo de aav modificado para tratamento de doença artrítica | |
| BR112022016965A2 (pt) | Polipeptídeos e vetores de capsídeo do vírus adenoassociado | |
| MX2020003095A (es) | Arni variante. | |
| BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
| CO2024006328A2 (es) | Composiciones útiles en el tratamiento del trastorno por deficiencia de cdkl5 (cdd) | |
| ES2554752T1 (es) | Sistema de baculovirus para expresar proteínas que forman partículas pseudovirales | |
| AR108781A1 (es) | Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv) | |
| CO2022016956A2 (es) | Composiciones útiles en el tratamiento del trastorno de deficiencia de cdkl5 (cdd) | |
| MX2022006496A (es) | Proteinas gpcr de opsinas quimericas. | |
| UY37975A (es) | Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos | |
| BR112023004871A2 (pt) | Métodos para reduzir o conteúdo de proteínas das células hospedeiras em processos de purificação de proteínas | |
| Xu et al. | Proteomic analysis of cellular protein expression profiles in response to grass carp reovirus infection | |
| AR123041A1 (es) | Transactivadores del dominio de unión al adn y usos de los mismos | |
| CO2026000794A2 (es) | Vector viral y célula productora | |
| BRPI1007979A2 (pt) | Anticorpos anti-mst1r e usos dos mesmos |